Morgan Stanley Downgrades Zenas BioPharma to Equal-Weight, Lowers Price Target to $19

Benzinga · 4d ago
Morgan Stanley analyst Judah Frommer downgrades Zenas BioPharma (NASDAQ:ZBIO) from Overweight to Equal-Weight and lowers the price target from $37 to $19.